{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:29:18Z","timestamp":1789223358015,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NCHHSTP-V147666-0"],"award-info":[{"award-number":["NCHHSTP-V147666-0"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ijantimicag.2016.05.018","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T14:16:00Z","timestamp":1468592160000},"page":"328-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione"],"prefix":"10.1016","volume":"48","author":[{"given":"John R.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-5216","authenticated-orcid":false,"given":"Kenneth","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samera","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Kirkcaldy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0010","series-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0015","series-title":"Antibiotic resistance threats in the United States, 2013","author":"US Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0025","series-title":"Sexually transmitted diseases treatment guidelines","author":"US Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0030","series-title":"Canadian guidelines on sexually transmitted infections: gonococcal infections","author":"Public Health Agency of Canada","year":"2013"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0035","series-title":"BASHH clinical effectiveness group guidelines","author":"British Association for Sexual Health and HIV","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0040","series-title":"Gonococcal Isolate Surveillance Project (GISP)","author":"US Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0045","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1473-3099(13)70143-9","article-title":"Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007\u20132011","volume":"13","author":"Ison","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0050","first-page":"332","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2958.1994.tb01297.x","article-title":"Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates","volume":"14","author":"Belland","year":"1994","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0060","first-page":"1","article-title":"Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases","volume":"5","author":"Basarab","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0065","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0070","doi-asserted-by":"crossref","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","article-title":"Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914","volume":"290","author":"Kern","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0075","author":"US Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0080","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0085","series-title":"Global incidence and prevalence of selected curable sexually transmitted infections\u20142008","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0090","series-title":"Gonorrhea statistics","author":"US Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0095","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.2015.10347","article-title":"Changing trends in Neisseria gonorrhoeae susceptibility to cephalosporins and its implications for gonorrhea treatment: sentinel surveillance data from the Gonococcal Isolate Surveillance Project, United States, 2006\u2013June 2014","volume":"314","author":"Kirkcaldy","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0100","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1128\/AAC.00786-15","article-title":"High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014","volume":"59","author":"Unemo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.05.018_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2015.01377","article-title":"Genetic resistance determinants, in vitro time\u2013kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae","volume":"6","author":"Foerster","year":"2015","journal-title":"Front Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916301595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916301595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:40:30Z","timestamp":1762321230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916301595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0924857916301595"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.05.018","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}